Clinical Trial Update: A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial compared ramucirumab plus eribulin to eribulin alone in breast cancer. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-08-19